Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.
about
Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.Exploratory Analysis of Associations Between Postmarketing Safety Events and Approved Doses of New Drugs in Japan.Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia.Driving Access to Medicines With a Totality of Evidence Mindset: An Opportunity for Clinical Pharmacology.Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
P2860
Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Toward Optimum Benefit-Risk an ...... nical Pharmacology Principles.
@en
type
label
Toward Optimum Benefit-Risk an ...... nical Pharmacology Principles.
@en
prefLabel
Toward Optimum Benefit-Risk an ...... nical Pharmacology Principles.
@en
P2093
P2860
P921
P356
P1476
Toward Optimum Benefit-Risk an ...... nical Pharmacology Principles.
@en
P2093
K Takeyama
K Venkatakrishnan
P2860
P356
10.1111/CTS.12386
P407
P5008
P577
2016-02-01T00:00:00Z
2016-02-02T00:00:00Z